Recently, clinical trials utilizing bisphosphonates, such as PAM and ZOL, to expand γδ-T cell in vivo in combination with IL-2 therapy or adoptive transfer of ex vivo cultured γδ-T cells were performed in patients with tumors and virus infections (11, 15, 58, 59). This evidence concerns the gene IL2 and viral infectious disease.